Josep Tabernero

Function ESMO Executive Board
Address Medical Oncology Department
Vall d’Hebron University Hospital


Josep Tabernero

Josep Tabernero holds MD and PhD degrees from the Universitat Autònoma de Barcelona, Spain. He is currently the Head of the Medical Oncology Department at the Vall d’Hebron University Hospital in Barcelona and the Director of the Vall d’Hebron Institute of Oncology.

He is very actively involved in translational research and pharmacodynamic phase I studies with molecular targeted therapies. He is especially devoted to phase I and II studies with pharmacodynamic endpoints with novel agents directed to the membrane receptors, like the EGFR-family and IGF-1R, the PI3K and ERK signalling pathways, as well as downstream cytoplasmatic and intranucleous effectors like Mdm2/p53 and aurora kinase. Based on the idea that each tumour has an independent genetic identity, the group he is leading very actively participates in the development of molecular therapies targeting specific oncoproteins, with the purpose of developing personalised therapies (e.g. against EGFR, HER2, BRAF, MEK, PI3K, Akt, mTOR or IGF1-R among others) for those patients displaying genetic lesions or pathway disregulation. One of the main objectives of the group is to identify new predictive markers of response to diverse treatments and to identify markers of primary resistance (de novo) and secondary treatment. At a preclinical level, the group he is leading is developing new xenograft models with explant tumors from patients (“xenopatients”) in mice in order to mimic the patient’s disease and study the tumor development in optimized research models. It also leads a program devoted to the study of circulating biomarkers (detection and genotyping of circulating free DNA).

Dr. Tabernero is a member of the Executive Board of the European Society for Medical Oncology (ESMO), and was Treasurer and Chair of Audit Committee until 2015. He has been elected ESMO President 2018-2019 and is currently serving as President-elect. He is a member of the ESMO Magnitude of Clinical Benefit Scale Working Group, the ESMO Public Policy Steering Committee and the ESMO Audit Committee.

He is also member of the American Association for Cancer Research (AACR) and the American Society of Clinical Oncology (ASCO), participating in its International Affairs Committee. He is actively involved in different editorial boards including the Journal of Clinical Oncology, Clinical Cancer Research, Cancer Discovery, Clinical Colorectal Cancer, Annals of Oncology and ESMO Open.

He has (co)authored approximately 250 peer-reviewed papers. He has also been a member of the Educational and Scientific Committees of the ESMO, ECCO, ASCO, AACR, AACR/NCI/EORTC, ASCO Gastrointestinal, and WCGIC meetings.